-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference
Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference
MALVERN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8 a.m. Eastern Time. Dr. Musunuri will discuss COVAXIN™, the investigational COVID-19 vaccine which the company is co-developing with Bharat Biotech for the U.S. and Canadian markets. He will also present information about Ocugen's breakthrough modifier gene therapy platform, which has generated product candidates that are expected to enter Phase 1/2a clinical trials in ophthalmic disease states over the next 18 months.
The fireside chat can be viewed live at https://wsw.com/webcast/cantor12/ocgn/2072070 and will be available within Ocugen's Investor Relations page found at https://ir.ocugen.com.
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — "one to many," and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as risks and uncertainties regarding market and other conditions and the timing of our planned clinical trials. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the "SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
IR@Ocugen.com
MALVERN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8 a.m. Eastern Time. Dr. Musunuri will discuss COVAXIN™, the investigational COVID-19 vaccine which the company is co-developing with Bharat Biotech for the U.S. and Canadian markets. He will also present information about Ocugen's breakthrough modifier gene therapy platform, which has generated product candidates that are expected to enter Phase 1/2a clinical trials in ophthalmic disease states over the next 18 months.
宾夕法尼亚州马尔文,9月环球新闻网2021年9月23日电专注于发现、开发和商业化治疗失明疾病的基因疗法和对抗新冠肺炎的疫苗的生物制药公司欧库根公司(纳斯达克市场代码:OCGN)今天宣布,其董事长、首席执行官兼联合创始人尚卡尔·穆苏努里博士将出席2021年9月28日(星期二)上午8点举行的2021年坎托虚拟全球医疗大会。东部时间。穆苏努里博士将讨论COVAXIN™,这是该公司与巴拉特生物技术公司在美国和加拿大市场共同开发的一种新冠肺炎研究疫苗。他还将介绍欧库根公司突破性的修饰剂基因治疗平台的信息,该平台已经产生了候选产品,预计将在未来18个月内进入眼科疾病状态的1/2a期临床试验。
The fireside chat can be viewed live at https://wsw.com/webcast/cantor12/ocgn/2072070 and will be available within Ocugen's Investor Relations page found at https://ir.ocugen.com.
炉边谈话可在https://wsw.com/webcast/cantor12/ocgn/2072070网站上现场观看,并可在欧库根公司投资者关系页面上观看,网址为https://ir.ocugen.com.。
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — "one to many," and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.
欧库根公司简介欧库根公司是一家生物制药公司,专注于发现、开发和商业化治疗失明疾病的基因疗法,并开发一种拯救新冠肺炎生命的疫苗。我们突破性的修饰基因治疗平台具有用一种药物“一对多”治疗多种视网膜疾病的潜力,我们的新型生物候选产品旨在为湿性老年性黄斑变性、糖尿病性黄斑水肿和糖尿病视网膜病变等服务不足的患者提供更好的治疗。我们正在共同开发巴拉特生物技术公司在美国和加拿大市场为新冠肺炎开发的COVAXIN™候选疫苗。欲了解更多信息,请访问www.ocugen.com。
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as risks and uncertainties regarding market and other conditions and the timing of our planned clinical trials. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the "SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
关于前瞻性陈述的警示说明本新闻稿包含1995年“私人证券诉讼改革法”所指的前瞻性陈述,这些陈述会受到风险和不确定性的影响。在某些情况下,我们可能会使用诸如“预测”、“相信”、“潜在”、“建议”、“继续”、“估计”、“预期”、“预期”、“计划”、“打算”、“可能”、“将”、“应该”或其他表达未来事件或结果不确定性的词语来识别这些前瞻性陈述。此类声明受许多重要因素、风险和不确定性的影响,这些因素可能会导致实际事件或结果与我们目前的预期大不相同,例如有关市场和其他条件的风险和不确定性以及我们计划的临床试验的时间。这些和其他风险和不确定性在我们提交给美国证券交易委员会(SEC)的定期报告中有更全面的描述,包括我们提交给SEC的季度和年度报告中题为“风险因素”一节中描述的风险因素。我们在本新闻稿中所作的任何前瞻性陈述仅限于本新闻稿发布之日。除非法律另有要求,否则我们没有义务在本新闻稿发布之日之后,因新信息、未来事件或其他原因而更新本新闻稿中包含的前瞻性陈述。
Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
IR@Ocugen.com
Ocugen联系人:肯·因乔斯蒂(Ken Inchausti)投资者关系和公关主管邮箱:ir@Ocugen.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧